Trade Star Group’s Pharmaceutical Industry Acquisition Making New Breakthrough—Trade Star and GSK Reaching Agreement to Acquire the Equity of Nanjing Meirui
On July 4th, 2016, our company has made into an agreement with GSK regarding the acquisition of Nanjing Meirui Equity. After the transition, our company will own all equity of Nanjing Meirui, and the business owned by Nanjing Meirui will be operated by our company.
Dr. Li Chao--Chairman of Trade Star and Mr. Brett—Director of Global Business Development GSK
First from the left: Mr. Brett—Director of Global Business Development GSK; Second from the left: Mr. Dominique—GSK Project Manager; Third from the left: Mr. Li Chao—Chairman of Trade Star; Fourth from the left: Ms. Nicola—GSK Legal Advisor
Nanjing Meirui is located in Nanjing, a city with favorable geographical location and transportation. As one of the manufacturing sites of GSK in China, it owns an internationally advanced manufacturing quality management system, and well-trained and highly experienced staff. Drugs such as Sheniting (quick release), Sheniting (controlled release) and Naftopidil Tablets are welcomed by the doctors and patients due to their great quality. This successful acquisition is beneficial to perfecting the layout of Trade Star’s pharmaceutical industry block, significantly enhancing the Group’s overall technical level of manufacturing quality management, and further enriching the Group’s product line. Trade Star will develop itself continuously by making full use of Nanjing Meirui’s manufacturing capacity, technical advantages and staff’s expertise, aiming at providing quality drug products for the patients and offering long-term development and growth opportunities for its staff.
ZYZHAN (China Pharmaceutical Net)